What are the DSS-II guidelines for bariatric surgery to treat type 2 diabetes mellitus?

Updated: May 28, 2019
  • Author: Alan A Saber, MD, MS, FACS, FASMBS; Chief Editor: John Geibel, MD, MSc, DSc, AGAF  more...
  • Print
Answer

In June 2016, the 2nd Diabetes Surgery Summit (DSS-II), an international consensus conference, issued the following global guidelines regarding the benefits and limitations of bariatric/metabolic surgery for type 2 diabetes mellitus [11] :

  • Metabolic surgery should be a  recommended option to treat type 2 diabetes mellitus in appropriate surgical candidates with class III obesity (BMI ≥40 kg/m 2), regardless of the level of glycemic control or complexity of glucose-lowering regimens, as well as in patients with class II obesity (BMI 35.0-39.9 kg/m 2) with inadequately controlled hyperglycemia despite lifestyle and optimal medical therapy
  • Metabolic surgery should also be  considered to be an option to treat type 2 diabetes in patients with class I obesity (BMI 30.0-34.9 kg/m 2) and inadequately controlled hyperglycemia despite optimal medical treatment by either oral or injectable medications (including insulin)
  • All BMI thresholds should be reconsidered depending on the ancestry of the patient; for example, for patients of Asian descent, the BMI values above should be reduced by 2.5 kg/m 2
  • Metabolic surgery should be performed in high-volume centers with multidisciplinary teams that understand and are experienced in the management of diabetes and gastrointestinal surgery
  • Ongoing and long-term monitoring of micronutrient status, nutritional supplementation, and support must be provided to patients after surgery, according to guidelines for postoperative management of bariatric/metabolic surgery by national and international professional societies
  • Metabolic surgery is a potentially cost-effective treatment option in obese patients with type 2 diabetes; the clinical community should work together with health care regulators to recognize metabolic surgery as an appropriate intervention for type 2 diabetes in people with obesity and to introduce appropriate reimbursement policies

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!